Contribute Try STAT+ Today

Over the past six months, more drug makers have begun posting their policies for gaining greater access to experimental medicines, according to a new analysis. However, more than half of all pharmaceutical manufacturers have yet to take this step to improve disclosure.

Specifically, 47 percent of 98 drug makers have posted a compassionate use policy on their web sites, compared with 19 percent last October. However, 84 percent of the 25 companies with a market capitalization of greater than $10 billion posted policies. This was up from 52 percent last fall.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Drug makers must agree to make their medicines available”. Ed, at this point I believe that companies can still opt to post “no access” on their website, so that I don’t think this statement is entirely correct.

    • Hi Pharmvet1,
      Thanks for the note. What I meant is that, drug makers must make their medicines available for patients to have access. Sorry for any semantic confusion.

Comments are closed.